Micah N. Sagini
Heidelberg, BW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
EPI-X4, a CXCR4 antagonist inhibits tumor growth in pancreatic cancer and lymphoma models.
Journal: Peptides
Published: August 06, 2023
Khasianine Affects the Expression of Sugar-Sensitive Proteins in Pancreatic Cancer Cells, Which Are Altered in Data from the Rat Model and Patients.
Journal: ACS pharmacology & translational science
Published: January 19, 2023
A subgroup of lactosyl-Sepharose binding proteins requires calcium for affinity and galactose for anti-proliferation.
Journal: Chemico-biological interactions
Published: October 14, 2020
Riproximin Exhibits Diversity in Sugar Binding, and Modulates some Metastasis-Related Proteins with Lectin like Properties in Pancreatic Ductal Adenocarcinoma.
Journal: Frontiers in pharmacology
Published: April 07, 2020
Lactosyl-sepharose binding proteins from pancreatic cancer cells show differential expression in primary and metastatic organs.
Journal: Experimental biology and medicine (Maywood, N.J.)
Published: March 06, 2020
Riproximin is a recently discovered type II ribosome inactivating protein with potential for treating cancer.
Journal: Biotechnology advances
Published: January 21, 2014
Showing 1-8 of 8
Last Updated: 09/26/2026